Objectives: To evaluate the impact of the 12-gene Colon Cancer Recurrence Score Assay-a clinically validated prognosticator in stage II colon cancer after surgical resection-on adjuvant treatment decisions in T3 mismatch repair proficient (MMR-P) stage II colon cancer in clinical practice. Methods: This retrospective analysis included all patients with T3 MMR-P stage II colon cancer (Clalit Health Services members) with Recurrence Score results (time frame January 2011 to May 2012). Treatment recommendations pretesting were compared with the treatments received. Changes were categorized as decreased (to observation alone/removing oxaliplatin from the therapy) or increased (from observation alone/adding oxaliplatin to the therapy) intensity. Results: The analysis included 269 patients; 58%, 32%, and 10% of the values were in the low (o30), intermediate (30) (31) (32) (33)(34)(35)(36)(37)(38)(39)(40), and high (Z41) score groups, respectively. In 102 patients (38%), treatment changed post-testing (decreased/increased intensity 76/26 patients). The overall impact was decreased chemotherapy use (45.0% to 27.9%; P o 0.001). Treatment changes occurred in all score groups, but more frequently in the high (change rate 63.0%; 95% confidence interval [CI] 42.3%-80.6%) than in the intermediate (30.6%; 95% CI 21.0%-41.5%) and low (37.6%; 95% CI 30.0%-45.7%) score groups. The direction of the change was consistent with the assay result, with increased intensity more common in higher score values and decreased intensity more common in lower score values. Conclusions: Testing significantly affected adjuvant treatment in T3 MMR-P stage II colon cancer in clinical practice. The study is limited by its design, which compared treatment recommendations pretesting to actual treatments received post-testing, lack of a control group, and nonassessment of confounding factors that may have affected treatment decisions.
Introduction
Colorectal cancer is the third most common cancer and the fourth leading cause of cancer death worldwide [1] . Globally, every year, colon and rectal cancers are diagnosed in 1.4 million individuals and lead to 700,000 deaths [1] . Approximately onequarter of the patients with colon cancer present with stage II disease [2] , in which the role of adjuvant chemotherapy remains controversial. In this patient population, the 5-year survival rate with surgery alone is 70% to 80% [3] and the evidence relating to the clinical benefit of 5-fluorouracil (5-FU)-based adjuvant chemotherapy regimens from individual studies and meta-analyses is inconsistent [4] [5] [6] [7] [8] [9] . The current National Comprehensive Cancer Network guidelines include adjuvant chemotherapy as a treatment option in this setting, particularly for high-risk stage II patients, as determined by clinical and pathological parameters [10] . Although some of the routinely used parameters for estimating recurrence risk such as T-stage and mismatch repair (MMR) status are well established, with T4 patients having higher recurrence risk and patients with MMR-deficient tumors having lower recurrence risk, other parameters, including tumor grade and lymphovascular invasion, may not be reliable predictors of recurrence risk in this population [11] [12] [13] [14] [15] [16] [17] . Most of the patients ($75%) with stage II colon cancer have T3 MMR-proficient (MMR-P) tumors [15] , and are therefore considered standard risk. These patients could therefore benefit from a tool that would further refine their risk of recurrence and facilitate individualized adjuvant treatment decisions.
The 12-gene Oncotype DX Colon Cancer Assay (Genomic Health, Inc., Redwood City, CA) is a reverse transcriptase polymerase chain reaction-based assay that provides a Recurrence Score (RS) result [18] . The assay has been clinically validated (level I, category B evidence [19] ) as a predictor of recurrence risk following surgical resection in patients with both stage II and III colon cancer in three validation studies [15, 16, 20] . The validation studies used archived samples from prospectively designed clinical trials (the Quick and Simple and Reliable study, the Cancer and Leukemia Group B 9581 study, and the National Surgical Adjuvant Breast and Bowel Project C-07 study), involving a total of 3018 patients. Together, these studies demonstrated that in stage II patients, the Recurrence Score result is an independent predictor of recurrence risk, along with T-stage and MMR status, and is able to predict the risk of recurrence beyond traditional clinical and pathological parameters [15, 16, 20] . Interestingly, a recent study involving 297 patients with stage II/III rectal cancer who were randomized to surgery alone in the Dutch total mesorectal excision (TME) trial demonstrated that the Recurrence Score result can predict recurrence risk in this population as well, suggesting a similar underlying biology in colon and rectal cancers [21] . In the United States, the 12-gene colon cancer assay has been commercially available for patients with stage II and stage III colon cancer who have undergone surgical resection since January 2010. In Israel, the assay has been reimbursed by Clalit Health Services (CHS; the largest health care organization in Israel with more than 4 million members) since January 2011.
Since the introduction of the 12-gene colon cancer assay, two additional colon cancer genomic assays have become available. Both of these assays-ColoPrint (Agendia NV, Amsterdam, The Netherlands) and ColDx assay (Almac Diagnostics, Craigavon, Northern Ireland)-use microarray technology for assessing the gene expression of 18 and 634 genes, respectively, and stratify patients into low and high recurrence risk groups [22] [23] [24] [25] . Both assays have been clinically validated using retrospective cohort studies (level IIIC or IV evidence [19] ).
Following establishment of the clinical validity of a diagnostic test, ascertaining its clinical utility (i.e., improved measureable clinical outcomes, usefulness, and added value for clinical decision making [26] ) is key for its incorporation into clinical practice and ultimately for determining cost-effectiveness. One approach for determining clinical utility is through decision impact studies. For the 12-gene colon cancer assay, two such studies were performed, both in the United States [27] [28] [29] ; the study reported herein addresses clinical practices outside the United States.
The aim of this study was to evaluate the impact of the 12-gene colon cancer assay on treatment decision making for patients with T3 MMR-P stage II colon cancer in a conventional clinical practice setting in Israel.
Methods

Study Design and Patient Population
This was a preplanned analysis of a prospectively designed registry. It included all patients with stage II colon cancer (treated in the seven participating institutions) who underwent the 12-gene colon cancer assay testing through CHS between January 2011 and May 2012. The analysis was restricted to patients with T3 MMR-P tumors. The study was approved by the institutional review board of the CHS as well as the institutional review boards of the participating institutions (Davidoff Cancer Center, Hadassah-Hebrew University Medical Center, Kaplan Medical Center, Lin Medical Center, Rambam Healthcare Campus, Soroka University Medical Center, and Tel Aviv Sourasky Medical Center). All patients signed an informed consent form.
Patient Flow and Data Source
Upon enrollment of patients into the registry, the treating physicians reported information on patients' baseline characteristics. Treatment recommendations before testing with the 12-gene colon cancer assay were specified by the treating physician (upon enrollment) using a questionnaire. The same treating physician reviewed the Recurrence Score results (received within 8-12 days of testing) and made treatment recommendations post-testing. In patients who received adjuvant chemotherapy, treatment initiation was typically within 1 week of receiving the test results. Actual treatments received post-testing were obtained from retrospective review of the CHS database.
Recurrence Score Result Determination
The Recurrence Score result is derived from referencenormalized gene expression measurements made by quantitative real-time reverse transcriptase polymerase chain reaction using RNA extracted from a fixed, paraffin-embedded tumor block obtained by surgical resection. The gene panel used for the assay comprises 12 genes: 7 cancer-related genes including 3 cell-cycle genes, 3 stromal genes, and the early response gene, GADD45B, and 5 reference genes [18] . Stromal group score and cell-cycle group score are calculated from reference-normalized individual gene expression measurements, and an unscaled RS (RS u ) result is determined using the following calculation: RS u ¼ (0.15 Â Stromal group score) À (0.3 Â Cell-cycle group score) þ (0.15 Â GADD45B). The Recurrence Score result is then rescaled from 0 to 100. Patients are categorized into three risk groups according to their Recurrence Score result: low (o30), intermediate (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) , and high (Z41) [18] .
Statistical Analysis
Descriptive statistics were used to summarize patient and tumor characteristics, treatment recommendations before testing with the 12-gene colon cancer assay, and actual treatments received after testing. For each patient, the treatment recommendation pretesting was compared with the actual treatment received (post-testing). Change in treatment was defined as either a decreased intensity change if the changes were to observation alone or to remove oxaliplatin from the adjuvant therapy; or an increased intensity change if the changes were from observation alone or to add oxaliplatin to the adjuvant therapy. Changes in treatment intensity were also evaluated according to the Recurrence Score groups, as defined in the Quick and Simple and Reliable study [15] . The McNemar test was used to assess whether the difference between the proportion of patients with chemotherapy recommendations (pretesting) and the proportion of patients actually receiving chemotherapy (post-testing) was significant. All analyses were conducted using SAS statistical software version 9.4 (SAS Institute Inc., Cary, NC); P o 0.05 was considered significant.
Results
Study Patients
Between January 2011 and May 2012, 312 patients with T3 stage II colon cancer underwent testing with the 12-gene colon cancer assay and MMR testing through the CHS (these patients constitute approximately 60% of the CHS patients with T3 stage II colon cancer diagnosed in this time frame). Thirty-nine of these 312 patients (12.5%) were found to have MMR-deficient tumors and were excluded from the present analysis. Of the 273 patients with MMR-P tumors, 269 patients (98.5%) were included in the primary analysis. Four patients were excluded: three did not have pretesting treatment recommendations, and one was excluded on the basis of pathology/laboratory exclusion criteria.
Patient characteristics were representative of the contemporary T3 stage II colon cancer patient population [30] (Table 1 ). The median Recurrence Score value was 28 (range 7-70), and the interquartile range was 22 to 34. More than half of the study patients (58.4%) had Recurrence Score values in the low, approximately one-third (31.6%) in the intermediate, and one-tenth (10.0%) in the high score (Table 1) groups.
Recurrence Score Results and Treatment Changes
In 102 patients (37.9%; 95% confidence interval [CI] 32.1%-44.0%), review of the Recurrence Score results by the physician affected treatment, resulting in a decrease in treatment intensity in 76 patients (28.2%; 95% CI 23.0%-34.0%) and an increase in treatment intensity in 26 patients (9.7%; 95% CI 6.4-13.8%) ( Table 2) .
The observed changes in treatment intensity led to a statistically significant change in the proportion of patients treated with chemotherapy (5-FU or 5-FU plus oxaliplatin; P o 0.001; McNemar test). The proportion of patients receiving chemotherapy decreased from 45.0% to 27.9%; observation increased from 55.0% to 72.1% (Fig. 1) .
Comparing the distribution of the Recurrence Score results by treatment (pretesting recommendation vs. post-testing actual treatment received) showed that the median Recurrence Score result shifted in all groups. It became lower in the observation group and higher in the chemotherapy groups (observation group: from 27 to 26; 5-FU group: from 28 to 34; 5-FU plus oxaliplatin group: from 28.5 to 41; Fig. 2 ).
Treatment changes were also analyzed by Recurrence Score groups. Although changes were noted in all groups, they occurred more frequently in the high-score group (change rate of 63.0%; 95% CI 42.3%-80.6%) than in the intermediate-score (30.6%; 95% CI 21.0%-41.5%) and low-score (37.6%; 95% CI 30.0%-45.7%) groups (Table 3 ). In the high-score group, increased treatment intensity changes were more common than decreased treatment intensity changes (40.7% vs. 22.2%), with most of the increased intensity changes from observation to chemotherapy (90.9%). In contrast, in the low-score group, decreased intensity changes were more common (35.0% vs 2.5%), with most of the decreased intensity changes from 5-FU monotherapy to observation (76.4%). In the intermediate-score group, the change rates were similar overall (17.6% and 12.9% for decreased and increased treatment intensity changes, respectively; Table 3 ).
In the high-score group, the observed changes in treatment intensity led to a net increase in chemotherapy use of 18.6% (from 40.7% to 59.3%), whereas in the low-score group, there was a net decrease in chemotherapy use of 30.6% (from 44.6% to 14.0%) (Fig. 1) .
Discussion
In this preplanned study using a prospectively designed registry in Israel-the first study outside the United States and potentially relevant to European clinical practice-we assessed the impact of the 12-gene colon cancer assay on patients with T3 MMR-P stage II colon cancer in real-life clinical practice. We showed that after The whiskers represent the 5% to 95% confidence intervals. Individual data points were overlaid on the box-whisker plot.
(Color version of figure is available online.)
that the Recurrence Score results influence treatment decisions in both directions by identifying lower-risk patients who are expected to gain smaller absolute benefits from chemotherapy and for whom chemotherapy and its associated toxicities could be avoided, as well as identifying high-risk patients who are expected to gain larger absolute benefits from chemotherapy. The rate of treatment recommendation change observed in our study is consistent with those of the two US studies in patients with stage II colon cancer: a retrospective analysis involving 92 evaluable patients of whom 68 had T3 MMR-P tumors and a prospective study involving 219 patients of whom 141 were evaluable and had T3 MMR-P tumors. In these studies, a change in treatment recommendations was observed in 26% and 45% of T3 MMR-P patients, respectively. Consistent with our findings, in both these studies, an overall net reduction in adjuvant chemotherapy recommendation was observed after testing [27] [28] [29] . Notably, in both US studies, the rate of chemotherapy recommendation pretesting (for all 92 patients in the retrospective study and for the 141 T3 MMR-P patients in the prospective study) appears to be higher than that in the present study (52%-57% vs. 45%). A potential explanation for this difference may be more frequent adjuvant chemotherapy use in patients with stage II colon cancer in the United States relative to Europe/Israel as reported in a recent study comparing population-based registries in the United States and across Europe [31] . Other explanations include study design and physician biases in ordering the 12-gene colon cancer assay or in enrolling patients in decision impact studies.
The net effect of the assay in our study was a reduction in adjuvant chemotherapy use compared with pretesting recommendations. This reduction could potentially minimize treatmentrelated morbidities in patients with T3 MMR-P stage II colon cancer and is expected to result in cost saving. A healtheconomic analysis, performed as a substudy of the prospective US-based study, demonstrated that treatment decisions based on incorporation of the 12-gene colon cancer assay would be expected to result in cost savings for the health care system [32] . A formal health-economic assessment of the effect of the 12-gene colon cancer assay in Israel is therefore warranted and underway.
The design of this study facilitated the assessment of the assay's impact in a real-life clinical setting. We consider the present study to constitute an accurate representation of current treatment trends for this population in Israel: the study included a large number of patients and physicians from both the academic and community settings; patient characteristics were consistent with those of stage IIA patients for whom adjuvant chemotherapy is considered; and 85% of the patients had 12 or more lymph nodes examined, indicating a high quality of surgery and pathology assessments.
The present study compared physicians' treatment recommendations before receiving the results of the 12-gene colon cancer assay with actual treatments received (post-testing). The study has limitations in its design, which lacked a control group, and in the fact that confounding factors that may have affected treatment decisions were not assessed (e.g., patients' preferences). Furthermore, pretesting recommendations may be influenced by the knowledge that patients will receive an assay result. Notably, because testing was performed after all the workup has been completed, the only difference in the information that a physician had to guide treatment recommendations/decisions from pretesting to post-testing was the Recurrence Score result.
In conclusion, consistent with previous reported studies in the US population [27] [28] [29] , Recurrence Score testing was found to significantly affect adjuvant treatment intensity (in both directions) in patients with T3 MMR-P stage II colon cancer in a real-life clinical setting that represents European clinical practice. This impact led to an overall net reduction in chemotherapy use, suggesting that Recurrence Score testing may lead to improved risk stratification and confidence in risk-adapted use of adjuvant chemotherapy and consequently to reduced treatment-related complications, as well as health care expenditures, in this patient population.
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